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Background: In patients with COPD, exacerbations are associated with poor quality of life and
may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD man-
agement. Indacaterol, a once-daily ultra-long-acting b2-agonist, has been shown to reduce ex-
acerbations in various studies. This pooled analysis evaluated the effect of indacaterol on
exacerbations versus placebo.
Methods: Six-month data were pooled from three randomized, double-blind, and placebo-
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106 J.A. Wedzicha et al.300 mg versus placebo (6 months); and indacaterol 150 mg versus placebo (6 months). All treat-
ments were administered oncedaily. Data from other treatment groups were excluded. All
three studies enrolled patients aged 40 years with moderate-to-severe COPD and smoking
history 20 pack-years. Time to exacerbation and exacerbation rate were analyzed.
Results: Overall, the pooled data set included 2716 patients (indacaterol 150 mg [nZ 746], in-
dacaterol 300 mg [nZ 819], placebo [nZ 1151]). Both indacaterol doses 150 and 300 mg signif-
icantly reduced the COPD exacerbation rates compared with placebo (Rate ratios, RR [95%
Confidence Interval, CI]: 0.69 [0.55e0.87], 0.71 [95% CI: 0.57e0.88] respectively; both
p Z 0.002). Over 6 months, indacaterol 150 and 300 mg also significantly prolonged the time
to first moderate-to-severe exacerbation versus placebo (Hazard ratios, HR [95% CI]: 0.74:
[0.59e0.93], p Z 0.009; 0.73 [0.59e0.90], p Z 0.004, respectively). At months 3 and 6, clin-
ically relevant improvements in lung function versus placebo were observed with indacaterol
150 mg (Least squares mean treatment differences: Month 3Z 170 mL; Month 6Z 160 mL) and
300 mg (170 mL at both time-points; all p < 0.001).
Conclusions: In this pooled analysis, both indacaterol doses, 150 and 300 mg, were associated
with significant reductions in exacerbations and significant improvements in bronchodilation
versus placebo. The results suggest once-daily indacaterol is an effective treatment option
for providing sustained bronchodilation and preventing exacerbations in patients with COPD.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is associated
with a progressive and accelerated decline in lung function
and worsening dyspnea, punctuated by episodes of acute
worsening of symptoms (i.e., exacerbations) requiring
additional specific pharmacological treatment and,
possibly, emergency or hospital care. Exacerbations are
associated with poor health-related quality of life [1,2] and
even a single severe exacerbation increases the risk of
mortality [3,4]. In addition, treating patients experiencing
exacerbations places a significant burden on healthcare
systems [5e7]. Prevention of exacerbations is, therefore,
an important management strategy [8] and also a key
objective for new pharmacological treatments for COPD.
Indacaterol is an inhaled ultra-long-acting b2-agonist [9],
providing 24-h bronchodilation with oncedaily dosing in pa-
tients with COPD [10,11]. Data from clinical trials have
indicated indacaterol to be effective in preventing exacer-
bations in patients with moderate-to-severe COPD [10,11],
although these studies were not designed or powered to
detect a difference in the risk of exacerbations and the
overall rate of exacerbations was low in all groups. We
therefore conducted an analysis of pooled data from three
placebo controlled studies to provide sufficient patient
numbers and event rates. The objective of this pooled
analysis was to evaluate the effect of indacaterol on time to
first COPD exacerbation and exacerbation rate over 6
months, compared with placebo. We also evaluated trough
forced expiratory volume in 1 s (FEV1) in the pooled data set.
Methods
Study design and patients
Data were pooled from three randomized, double-blind,
placebo-controlled studies, namely, INVOLVE [10], INHANCE[11], and INLIGHT-2 [12] where exacerbations were one of
the secondary endpoints. INVOLVE compared indacaterol
300 mg once daily with placebo taken for 1 year [10];
INHANCE compared once-daily indacaterol 150 mg, indaca-
terol 300 mg and placebo taken for 6 months [11]; and
INLIGHT-2 compared indacaterol 150 mg once daily with
placebo, taken for 6 months [12]. Data from the other
treatment groups in these studies were excluded from this
pooled analysis since indacaterol 600 mg, and formoterol,
salmeterol and tiotropium were administered only in one
study and not across the three studies.
All three studies, which are source of the pooled data,
enrolled men and women aged 40 years with moderate-
to-severe COPD, that is, post-bronchodilator FEV1 <80% and
30% predicted and FEV1/forced vital capacity (FVC) < 70%
[13] (defined by Global Initiative for Chronic Obstructive
Lung Disease [GOLD] 2005 spirometric criteria). Patients
had to have a smoking history 20 pack-years. Excluded
from the studies were patients with a history of asthma, or
a recent (within 6 weeks prior to start of study) COPD
exacerbation or respiratory tract infection.
In all three studies included in this pooled analysis,
inhaled corticosteroids (ICS) were permitted, if stable for 1
month prior to screening; the dose and regimen were to
remain stable throughout the study. Patients previously on
fixed ICS/long-acting b2-agonist combinations were
switched to equivalent ICS monotherapy at a dose/regimen
maintained throughout the study. Salbutamol was available
as a rescue medication throughout the study.
Full details of the designs and enrolment criteria of the
individual studies have been published previously [10e12].
These studies were also registered at clinicaltrials.gov
under the following numbers: NCT00393458 [10],
NCT00463567 [11], and NCT00567996 [12]. All three studies
were conducted in accordance with the Declaration of
Helsinki (1989) and local applicable laws and regulations.
Approval was obtained from the Institutional Review Board
or Independent Ethics Committee of each participating
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sent prior to participating in each study included in the
pooled analysis.
Assessments and variables
COPD exacerbation was one of the secondary objectives in
the studies. COPD exacerbations were defined as the onset
or worsening of more than one respiratory symptom (dys-
pnea, cough, sputum purulence or volume, or wheeze) for
>3 days, together with intensified treatment (e.g. steroids,
antibiotics or oxygen) and/or hospitalization or emergency
room visit. All COPD exacerbation episodes that occurred
throughout the studies were recorded in the databases.
Spirometry was performed at screening, at baseline, and at
regular clinic visits during the studies, according to recog-
nized standards. The primary efficacy endpoint in all three
studies was ‘trough’ FEV1 (average of the 23 h 10 min and
23 h 45 min post-dose measurements) after 3 months of
treatment. In each study, a difference between indacaterol
and placebo of 120 mL in FEV1 was pre-specified as a min-
imal clinically important difference (MCID). Trough FEV1
was also measured after 6 months.
Statistical analysis
Analyses included all randomized patients who received at
least one dose of study drug with patients analyzed ac-
cording to the treatment to which they were randomized.
The frequency (rate) of exacerbations was analyzed using a
negative binomial model. The model included terms for
treatment, smoking status, ICS use, baseline COPDTable 1 Demographic and clinical characteristics at baseline.
Indacaterol 15
Patients, N 746
Age, years 63.3 (9.08)
Male, % 66.6
Ex-/current smoker, % 54.6/45.4
COPD duration, years 6.8 (6.56)
ICS use, % 41.3
Patients with an exacerbation leading
to hospitalization in the year prior
to entry, n (%)
43 (5.8)
GOLD 2005 [13] stage, n (%)a
Stage I or II 448 (60.1)
Stage III or IV 298 (40.0)
FEV1, % predicted
c 55.1 (14.28)
FEV1, L
Pre-bronchodilatorb 1.3 (0.48)
Post-bronchodilatorc 1.5 (0.50)
FEV1 reversibility, % 13.9 (15.49)
FEV1/FVC,
c % 53.2 (9.98)
Data are mean (SD) unless otherwise stated.
a GOLD 2005 was applicable when the 3 studies were initiated, Stag
GOLD 2013 strategy document.
b Assessed before administration of salbutamol 400 mg.
c Assessed 30 min after administration of salbutamol 400 mg.exacerbation history, baseline FEV1 reversibility compo-
nents, baseline percentage of days of poor control, study,
and country. The time at risk for a patient was defined as
the length of time the patient was in the study and the log
(length of time in the study) was used as the offset variable
in the model. This analysis included all exacerbation epi-
sodes recorded in the clinical database that occurred
within 6 months of first dose of study treatment.
Time to first exacerbation was calculated by the Kaplan
Meier method, analyzed using a Cox regression model. The
Cox regression model was stratified by country and study
and included the terms for treatment, smoking status, ICS
use, baseline COPD exacerbation history (yes/no), baseline
percentage of days of poor control and FEV1 reversibility
components. This analysis focused on the first exacerbation
episode only.
Trough FEV1 at Months 3 and 6 was analyzed using a
mixed model. The model contained treatment, smoking
status, ICS use, country and study as fixed effects. Addi-
tionally baseline FEV1 and FEV1 reversibility components
and a random effect of center within country were included
as covariates. Missing values were imputed by carrying
forward the last observation, but not by more than 14
weeks (for Month 6).Results
Baseline demographics and clinical characteristics
The pooled dataset included 2716 patients (746 received
indacaterol 150 mg, 819 received indacaterol 300 mg and
1151 received placebo), of whom 76% completed six0 mg Indacaterol 300 mg Placebo
819 1151
63.8 (8.90) 63.8 (8.47)
70.8 72.2
56.7/43.4 56.7/43.4
6.9 (6.77) 6.7 (6.12)
47.4 44.2
41 (5.0) 72 (6.3)
483 (59.0) 662 (57.5)
336 (41.0) 489 (42.5)
54.9 (14.03) 54.3 (14.21)
1.3 (0.46) 1.3 (0.47)
1.5 (0.49) 1.5 (0.49)
13.8 (14.21) 13.9 (16.06)
51.7 (10.41) 52.7 (10.56)
es I-IV in GOLD 2005 are the same as air flow limitation criteria in
Table 2 Distribution of patients by frequency of exacer-
bations over 6 months by treatment group.
N Frequency of exacerbations
over 6 months, number
of patients (%)
0 1 2 3
Indacaterol
150 mg
746 615 (82.4) 106 (14.2) 21 (2.8) 4 (0.5)
Indacaterol
300 mg
819 670 (81.8) 117 (14.3) 22 (2.7) 10 (1.2)
Placebo 1151 904 (78.5) 191 (16.6) 37 (3.2) 19 (1.7)
108 J.A. Wedzicha et al.months’ treatment. Baseline demographic and clinical
characteristics were similar between groups (Table 1).
Rate of exacerbations
The majority of patients in all three groups experienced no
exacerbations. Exacerbations occurred in 131 (17.5%), 149
(18.2%) and 247 (21.5%) patients in the indacaterol 150 mg,
300 mg and placebo groups, respectively. The proportions of
patients experiencing 0, 1, 2 and 3 exacerbations over the
treatment period are presented in Table 2.
Adjusting for treatment exposure, the annualized COPD
exacerbation rates were 0.49 for indacaterol 150 mg, 0.53
for indacaterol 300 mg and 0.69 for placebo. Exacerbation
rates were significantly reduced with both indacaterol 150
and 300 mg versus placebo, resulting in reductions of 31%
(Rate ratio [RR] 0.69, 95% CI 0.55e0.87) and 29% (RR 0.71,
95% CI 0.57e0.88) respectively, both p Z 0.002 (Fig. 1).
The Kaplan Meier plot of time to first moderate or severe
COPD exacerbation by treatment is in Fig. 2. Indacaterol
150 and 300 mg significantly prolonged the time to first
moderate-to-severe exacerbation over 6 months, with
hazard ratios [HR] versus placebo of 0.74 (95% CI:
0.59e0.93, p Z 0.009) and 0.73 (0.59e0.90, p Z 0.004),
respectively.Figure 1 Annualized ratesLung function
At Month 3, trough FEV1 was significantly improved with
indacaterol 150 and 300 mg compared with placebo, and the
improvements were sustained until Month 6 for both inda-
caterol doses, with the mean treatment effect exceeding
the pre-specified MCID threshold (all p < 0.001; Fig. 3).
Discussion
To date, relatively few studies have been specifically
designed to prospectively examine the role of bronchodi-
lators on exacerbations in patients with moderate-to-
severe COPD. One particular challenge in this population
is that the frequency of exacerbations is lower in patients
with moderate-to-severe COPD compared with those with
severe-to-very severe COPD [14], thus, in order to
adequately power the studies evaluating the effect of
treatment on reducing exacerbations in patients with
moderate-to-severe COPD, larger patient numbers are
required. Indacaterol has been shown to reduce the rate of
exacerbations in individual placebo-controlled phase III
studies [10e12], but the reduction was not always statis-
tically significant as those studies were not powered to
investigate the impact on exacerbations. Although the
optimal method to assess the impact of indacaterol on
exacerbations in patients with moderate-to-severe COPD
would be to conduct an adequately powered, prospective
trial, pooling data from these individual studies provides
sufficient patient numbers to evaluate the effect of inda-
caterol on reducing exacerbations in patients with COPD,
and permits some conclusions, which cannot be necessarily
drawn from individual studies, to be drawn. The data from
this pooled analysis showed that, compared with the pa-
tients on placebo, patients treated with indacaterol 150
and 300 mg, experienced lower rates of exacerbations, by
31% and 29%, respectively. These findings are consistent
with the observations from the individual studies where the
rate reductions relative to placebo were 33% for indaca-
terol 150 mg [11] and 18% and 25% for indacaterol 300 mgof COPD exacerbations.
Figure 2 Kaplan Meier plot of time to first moderate or severe COPD exacerbation.
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consistently reach statistical significance in these individual
studies. When studying the impact of pharmacologic in-
terventions on the incidence of COPD exacerbations, a six
month duration is a relatively short period for such evalu-
ations, with longer exposures to be preferred. This is due
both to the low incidence of such events, and their seasonal
nature. However, by comparing active arms with data from
the placebo group conclusions can still be drawn from the
6-month exposure of the current analysis. The three studies
pooled in this analysis recruited patients with moderate-to-
severe COPD, without consideration of their exacerbation
history. As a consequence, the results are more likely to beFigure 3 Effect of active treatments (differences compared
with placebo) on trough FEV1 at Months 3 and 6.indicative of the effectiveness of indacaterol in a broad
COPD population rather than in the subset of patients who
experience frequent exacerbations e the population typi-
cally recruited into exacerbations studies.
Bronchodilators are the mainstay of pharmacological
treatment for COPD. These long acting bronchodilators
provide sustained bronchodilation and improve airflow in
COPD patients, thereby reducing static and dynamic hy-
perinflation and consequently causing a reduction in dys-
pnea [15,16]. In addition, the reduction of hyperinflation by
bronchodilators can lead to decreased ventilation-
perfusion imbalance, which may minimize the patients
risk to triggers of exacerbations [17]. Indeed improvement
in hyperinflation has been shown to be better correlated
with improvements in exacerbation frequency than with
FEV1 alone [18]. Moreover, as exacerbations are associated
with an acute increase in hyperinflation, which may
contribute to the characteristic symptom of acute wors-
ening of dyspnea [19], bronchodilators, by deflating the
lungs, can help reduce the elastic load on inspiratory
muscle, and relieve symptoms such as dyspnea [20]. While
further studies are needed, there is some evidence indi-
cating that long-acting b2-agonist (LABAs) and LAMAs may
also improve airway or systemic lung inflammation [21,22],
thereby helping to further reduce the incidence of
exacerbations.
Most of the studies that examined the effect of bron-
chodilators on exacerbations have been conducted in pa-
tients at increased risk of exacerbations (who had a history
of exacerbations with or without severe airflow limitation)
[23e26]. However, this post-hoc pooled analysis included a
broader patient population to evaluate the impact of
indacaterol, a once-daily LABA, on exacerbations in such a
population. In current treatment guidelines, combination
therapy including ICS has been recommended for prevent-
ing exacerbations e but only in patients at high risk of
110 J.A. Wedzicha et al.exacerbating. Monotherapy bronchodilators are recom-
mended as optimal for patients who are not at high risk of
exacerbations [8]; for these patients, avoidance of the use
of ICS would also spare the added risk of adverse events
(such as the small risk of pneumonia) that has been asso-
ciated with long-term use of ICS in patients with COPD
[27e29].
In the 2013 update of the GOLD strategy document,
management of symptoms is considered an important part
of individualized treatment including risk of exacerbations
as a component of the overall assessment of COPD [8].
Besides reducing exacerbations demonstrated in this
pooled analysis, it is evident from the published results of
the individual studies included in this analysis, that
compared with placebo, indacaterol 150 and 300 mg doses
also provided clinically relevant improvements in lung
function at months 3 and 6, as well as improving a range of
symptomatic endpoints, including dyspnea (Transition Dys-
pnea Index), health status (St George’s Respiratory Ques-
tionnaire) and reduced rescue medication use [10e12]. The
lower number of exacerbations observed with indacaterol
in this current analysis further supports its use as a long
acting bronchodilator for patients with COPD. In all the
three studies included in this pooled analysis, indacaterol
was well tolerated and had an acceptable profile of cardio-
and cerebrovascular safety [30].
Conclusions
In this pooled analysis, indacaterol 150 and 300 mg
oncedaily showed a reduction in risk (by prolonging time to
first exacerbation) and rate of COPD exacerbations versus
placebo. The results from this pooled analysis, which are
consistent with those from earlier individual indacaterol
studies, suggest that indacaterol may be an effective
therapeutic option in patients with COPD.
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